{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:56:59Z","timestamp":1792796219889,"version":"4.5.0"},"reference-count":49,"publisher":"Portland Press Ltd.","issue":"5","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Human antibody-based therapeutics display characteristic N-glycan profiles that are critical determinants of developability, safety, pharmacokinetics, and efficacy. Although fragment crystallizable (Fc) engineering strategies to modulate effector functions are well established, comparatively less is known about how Fc mutations designed to enhance Fc effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity, influence Fc glycosylation. In the present study, we evaluated the impact of several ADC-enhancing Fc mutations (S239D\/I332E, D280H\/K290S, S239D\/A330L\/I332E, S298A\/E333A\/K334A, F243L\/R292P\/Y300L\/V305I\/P396L) on N-glycan composition and Fc-mediated activity. These mutations are spatially distinct from the N297 glycosylation site. Among the variants examined, antibodies containing the F243L\/R292P\/Y300L\/V305I\/P396L (LPLIL) mutations exhibited elevated levels of high-mannose glycans (Man5\u20139) when expressed in either CHO (Chinese hamster ovary) or HEK293 (human embryonic kidney 293) mammalian cells. Comparative glycan profiling revealed that differences in galactosylation and mannosylation between CHO- and HEK293-derived antibodies influenced CD16A binding affinity and ADCC activity across Fc variants. Notably, LPLIL-containing antibodies consistently demonstrated altered glycosylation patterns associated with enhanced effector function. Collectively, our findings demonstrated that ADCC-enhancing Fc mutations could substantially modify N-glycan composition, which in turn modulated Fc receptor engagement and downstream effector functions. These results highlighted the importance of evaluating glycosylation changes during Fc engineering to ensure optimal therapeutic performance.<\/jats:p>","DOI":"10.1042\/bcj20253380","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:00:40Z","timestamp":1774353640000},"page":"671-684","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of ADCC-enhancing mutations on\n                    <i>N<\/i>\n                    -glycan profiles of human IgG1 antibodies"],"prefix":"10.1042","volume":"483","author":[{"given":"Lu","family":"Han","sequence":"first","affiliation":[{"name":"1Research & Development Department, Tavotek Biotherapeutics, Suzhou 215000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[{"name":"1Research & Development Department, Tavotek Biotherapeutics, Suzhou 215000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6300-404X","authenticated-orcid":false,"given":"Mark\u00a0L.","family":"Chiu","sequence":"additional","affiliation":[{"name":"1Research & Development Department, Tavotek Biotherapeutics, Suzhou 215000, China"},{"name":"2Research & Development Department, Tavotek Biotherapeutics, Spring House, Pennsylvania 19102, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"2026041411362791700_B1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/07388551.2020.1869684","article-title":"Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development","volume":"41","author":"Kaur","year":"2021","journal-title":"Crit. Rev. Biotechnol."},{"key":"2026041411362791700_B2","doi-asserted-by":"publisher","first-page":"339828","DOI":"10.1016\/j.aca.2022.339828","article-title":"N-Glycosylation of monoclonal antibody therapeutics: a comprehensive review on significance and characterization","volume":"1209","author":"Shrivastava","year":"2022","journal-title":"Anal. Chim. Acta"},{"key":"2026041411362791700_B3","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3109\/07388551.2015.1084266","article-title":"Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives","volume":"36","author":"Dumont","year":"2016","journal-title":"Crit. Rev. Biotechnol."},{"key":"2026041411362791700_B4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s12257-018-0109-8","article-title":"Effect of environmental parameters on glycosylation of recombinant immunoglobulin G produced from recombinant CHO cells","volume":"23","author":"Kim","year":"2018","journal-title":"Biotechnol. Bioprocess Eng."},{"key":"2026041411362791700_B5","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.xphs.2018.11.029","article-title":"The mechanistic impact of N-glycosylation on stability, pharmacokinetics, and immunogenicity of therapeutic proteins","volume":"108","author":"Zhou","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"2026041411362791700_B6","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.tibtech.2020.05.009","article-title":"The formidable challenge of controlling high mannose-type N-Glycans in therapeutic mAbs","volume":"38","author":"Mastrangeli","year":"2020","journal-title":"Trends Biotechnol."},{"key":"2026041411362791700_B7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/jps.21504","article-title":"Effects of glycosylation on the stability of protein pharmaceuticals","volume":"98","author":"Sol\u00e1","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"2026041411362791700_B8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/bit.27953","article-title":"The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions","volume":"119","author":"Wang","year":"2022","journal-title":"Biotechnol. Bioeng."},{"key":"2026041411362791700_B9","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.xphs.2022.06.014","article-title":"Effect of the ADCC-modulating mutations and the selection of human IgG isotypes on physicochemical properties of Fc","volume":"111","author":"Wu","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"2026041411362791700_B10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.4161\/mabs.28588","article-title":"Influence of glycosylation pattern on the molecular properties of monoclonal antibodies","volume":"6","author":"Zheng","year":"2014","journal-title":"MAbs"},{"key":"2026041411362791700_B11","doi-asserted-by":"publisher","first-page":"e0134949","DOI":"10.1371\/journal.pone.0134949","article-title":"In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity","volume":"10","author":"Thomann","year":"2015","journal-title":"PloS One"},{"key":"2026041411362791700_B12","doi-asserted-by":"publisher","first-page":"e0143520","DOI":"10.1371\/journal.pone.0143520","article-title":"Multi-angle effector function analysis of human monoclonal IgG glycovariants","volume":"10","author":"Dashivets","year":"2015","journal-title":"PloS ONE"},{"key":"2026041411362791700_B13","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1074\/jbc.M111.297697","article-title":"Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc","volume":"287","author":"Latypov","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2026041411362791700_B14","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/jps.23975","article-title":"Physical stability comparisons of IgG1-Fc variants: effects of N-glycosylation site occupancy and Asp\/Gln residues at site Asn 297","volume":"103","author":"Alsenaidy","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"2026041411362791700_B15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.4161\/mabs.3.6.17922","article-title":"The impact of glycosylation on monoclonal antibody conformation and stability","volume":"3","author":"Zheng","year":"2011","journal-title":"MAbs"},{"key":"2026041411362791700_B16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jchromb.2019.04.031","article-title":"Glycan analysis for protein therapeutics","volume":"1120","author":"Yang","year":"2019","journal-title":"J. Chromatogr. B"},{"key":"2026041411362791700_B17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.4161\/mabs.20737","article-title":"Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans","volume":"4","author":"Yu","year":"2012","journal-title":"MAbs"},{"key":"2026041411362791700_B18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/glycob\/cwl057","article-title":"Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types","volume":"17","author":"Kanda","year":"2007","journal-title":"Glycobiology"},{"key":"2026041411362791700_B19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/glycob\/cwr027","article-title":"High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans","volume":"21","author":"Goetze","year":"2011","journal-title":"Glycobiology"},{"key":"2026041411362791700_B20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/glycob\/cwn120","article-title":"The effect of Fc glycan forms on human IgG2 antibody clearance in humans","volume":"19","author":"Chen","journal-title":"Glycobiology"},{"key":"2026041411362791700_B21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejpb.2019.03.018","article-title":"N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance","volume":"139","author":"Higel","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2026041411362791700_B22","doi-asserted-by":"publisher","first-page":"36964","DOI":"10.1038\/srep36964","article-title":"Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans","volume":"6","author":"Dekkers","year":"2016","journal-title":"Sci. Rep."},{"key":"2026041411362791700_B23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/19420862.2018.1551044","article-title":"Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms","volume":"11","author":"Wada","year":"2019","journal-title":"MAbs"},{"key":"2026041411362791700_B24","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/bit.20151","article-title":"Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"87","author":"Yamane-Ohnuki","year":"2004","journal-title":"Biotechnol. Bioeng."},{"key":"2026041411362791700_B25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.coi.2008.06.007","article-title":"Terminal sugars of Fc glycans influence antibody effector functions of IgGs","volume":"20","author":"Raju","year":"2004","journal-title":"Curr. Opin. Immunol."},{"key":"2026041411362791700_B26","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3389\/fimmu.2017.00877","article-title":"Decoding the human immunoglobulin G-Glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities","volume":"8","author":"Dekkers","year":"2017","journal-title":"Front. Immunol."},{"key":"2026041411362791700_B27","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1634\/theoncologist.2008-0089","article-title":"The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy","volume":"13","author":"Zhou","year":"2008","journal-title":"Oncologist"},{"key":"2026041411362791700_B28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000479980","article-title":"Modulating cytotoxic effector functions by Fc engineering to improve cancer therapy","volume":"44","author":"Kellner","year":"2017","journal-title":"Transfusion Med. Hemotherapy"},{"key":"2026041411362791700_B29","doi-asserted-by":"publisher","first-page":"eadd8005","DOI":"10.1126\/sciimmunol.add8005","article-title":"Fc glycoengineering of a PD-L1 antibody harnesses Fc\u03b3 receptors for increased antitumor efficacy","volume":"8","author":"Cohen Saban","year":"2023","journal-title":"Sci. Immunol."},{"key":"2026041411362791700_B30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG Fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2017","journal-title":"Protein Cell"},{"key":"2026041411362791700_B31","doi-asserted-by":"publisher","first-page":"8882","DOI":"10.1158\/0008-5472.CAN-07-0696","article-title":"Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors","volume":"67","author":"Stavenhagen","year":"2007","journal-title":"Cancer Res."},{"key":"2026041411362791700_B32","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R","volume":"276","author":"Shields","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2026041411362791700_B33","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1073\/pnas.0508123103","article-title":"Engineered antibody Fc variants with enhanced effector function","volume":"103","author":"Lazar","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026041411362791700_B34","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2026041411362791700_B35","doi-asserted-by":"publisher","first-page":"2415333","DOI":"10.1080\/19420862.2024.2415333","article-title":"Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan","volume":"16","author":"Mukai","year":"2024","journal-title":"Mabs"},{"key":"2026041411362791700_B36","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.molimm.2007.10.042","article-title":"Structural characterization of a mutated, ADCC-enhanced human Fc fragment","volume":"45","author":"Oganesyan","year":"2008","journal-title":"Mol. Immunol."},{"key":"2026041411362791700_B37","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0022-2836(02)01250-0","article-title":"Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity","volume":"325","author":"Krapp","year":"2003","journal-title":"J. Mol. Biol."},{"key":"2026041411362791700_B38","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"2026041411362791700_B39","doi-asserted-by":"publisher","first-page":"878.e875","DOI":"10.1016\/j.str.2017.04.014","article-title":"Fcab-HER2 interaction: a menage a; Trois. Lessons from X-Ray and solution studies","volume":"25","author":"Lobner","year":"2017","journal-title":"Structure"},{"key":"2026041411362791700_B40","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.tibtech.2016.02.013","article-title":"N-Glycosylation design and control of therapeutic monoclonal antibodies","volume":"34","author":"Sha","year":"2016","journal-title":"Trends Biotechnol."},{"key":"2026041411362791700_B41","doi-asserted-by":"publisher","first-page":"11957","DOI":"10.1038\/s41598-019-48323-w","article-title":"The Fab portion of immunoglobulin G contributes to its binding to Fc\u03b3 receptor III","volume":"9","author":"Yogo","year":"2019","journal-title":"Sci. Rep."},{"key":"2026041411362791700_B42","doi-asserted-by":"publisher","first-page":"114205","DOI":"10.1016\/j.ab.2021.114205","article-title":"High-throughput and high-sensitivity N-Glycan profiling: a platform for biopharmaceutical development and disease biomarker discovery","volume":"623","author":"Xie","year":"2021","journal-title":"Anal. Biochem."},{"key":"2026041411362791700_B43","doi-asserted-by":"publisher","first-page":"1750794","DOI":"10.1080\/19420862.2020.1750794","article-title":"A rapid method for relative quantification of N-glycans from a therapeutic monoclonal antibody during trastuzumab biosimilar development","volume":"12","author":"Segu","year":"2020","journal-title":"Mabs"},{"key":"2026041411362791700_B44","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/annonc\/mdx002","article-title":"First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors","volume":"28","author":"Bang","year":"2017","journal-title":"Ann. Oncol."},{"key":"2026041411362791700_B45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00280-005-1026-z","article-title":"Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer","volume":"56","author":"Bruno","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2026041411362791700_B46","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1200\/JCO.2005.03.184","article-title":"Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer","volume":"23","author":"Agus","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"2026041411362791700_B47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ddtec.2021.02.003","article-title":"Recent advances in CHO cell line development for recombinant protein production","volume":"38","author":"Tihanyi","year":"2020","journal-title":"Drug Discov. Today: Technol."},{"key":"2026041411362791700_B48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semcdb.2014.11.006","article-title":"Glycan regulation of ER-associated degradation through compartmentalization","volume":"41","author":"Benyair","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"2026041411362791700_B49","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/bit.25318","article-title":"Recent advances in the understanding of biological implications and modulation methodologies of monoclonal antibody N-linked high mannose glycans","volume":"111","author":"Shi","year":"2014","journal-title":"Biotechnol. Bioeng."}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/483\/5\/671\/986316\/bcj-2025-3380.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/483\/5\/671\/986316\/bcj-2025-3380.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:36:33Z","timestamp":1776180993000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/483\/5\/671\/237351\/Effect-of-ADCC-enhancing-mutations-on-N-glycan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,6]]}},"URL":"https:\/\/doi.org\/10.1042\/bcj20253380","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,13]]}}}